Literature DB >> 28801933

MALDI Imaging-Guided Microproteomic Analyses of Heterogeneous Breast Tumors-A Pilot Study.

Deborah Alberts1, Charles Pottier2, Nicolas Smargiasso1, Dominique Baiwir3, Gabriel Mazzucchelli1, Philippe Delvenne2, Mark Kriegsmann4, Daniel Kazdal4, Arne Warth4, Edwin De Pauw1, Rémi Longuespée1,4,5.   

Abstract

Matrix-assisted laser desorption/ionization (MALDI) imaging is an ideal tool to study intratumor heterogeneity (ITH) and its implication in prognostic stratification of patients. However, there are some drawbacks concerning protein identification. On the other hand, laser microdissection (LMD)-based microproteomics allows retrieving thousands of protein identifications from small tissue pieces. As a proof of concept, the authors combine these two complementary approaches to analyze heterogeneous regions in breast tumors. Invasive ductal breast cancer FFPE tissue sections from five patients are analyzed by MALDI imaging and the dataset is processed by segmentation. Heterogeneous regions within tumors are processed by LMD-based microproteomics, in duplicates. Liquid chromatography-tandem mass spectrometry data are classified by hierarchical clustering. Heterogeneous tissue regions are discriminated on the basis of their actual molecular heterogeneity. The dataset is correlated with MALDI imaging to identify m/z values discriminating heterogeneous regions. The molecular characterization of cell clones in tumors related to bad patient outcome could have great impact for pathology. A combined application of LMD-based microproteomics and MALDI imaging for ITH studies is presented.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Intratumor heterogeneity; Laser microdissection; MALDI imaging; Microproteomics

Mesh:

Substances:

Year:  2017        PMID: 28801933     DOI: 10.1002/prca.201700062

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  8 in total

1.  Metabolomics technology and bioinformatics for precision medicine.

Authors:  Rajeev K Azad; Vladimir Shulaev
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

Review 2.  Protein identification strategies in MALDI imaging mass spectrometry: a brief review.

Authors:  Daniel J Ryan; Jeffrey M Spraggins; Richard M Caprioli
Journal:  Curr Opin Chem Biol       Date:  2018-11-23       Impact factor: 8.822

3.  ImShot: An Open-Source Software for Probabilistic Identification of Proteins In Situ and Visualization of Proteomics Data.

Authors:  Wasim Aftab; Shibojyoti Lahiri; Axel Imhof
Journal:  Mol Cell Proteomics       Date:  2022-05-13       Impact factor: 7.381

4.  Whole Cell MALDI Fingerprinting Is a Robust Tool for Differential Profiling of Two-Component Mammalian Cell Mixtures.

Authors:  Valentina Z Petukhova; Alexandria N Young; Jian Wang; Mingxun Wang; Andras Ladanyi; Rajul Kothari; Joanna E Burdette; Laura M Sanchez
Journal:  J Am Soc Mass Spectrom       Date:  2018-10-23       Impact factor: 3.109

Review 5.  Overview on Clinical Relevance of Intra-Tumor Heterogeneity.

Authors:  Giorgio Stanta; Serena Bonin
Journal:  Front Med (Lausanne)       Date:  2018-04-06

6.  MALDI-IMS combined with shotgun proteomics identify and localize new factors in male infertility.

Authors:  Shibojyoti Lahiri; Wasim Aftab; Lena Walenta; Leena Strauss; Matti Poutanen; Artur Mayerhofer; Axel Imhof
Journal:  Life Sci Alliance       Date:  2021-01-06

Review 7.  Mass spectrometry-based characterization of histones in clinical samples: applications, progress, and challenges.

Authors:  Roberta Noberini; Giulia Robusti; Tiziana Bonaldi
Journal:  FEBS J       Date:  2021-01-23       Impact factor: 5.622

8.  Label-Free Mass Spectrometry-Based Quantification of Linker Histone H1 Variants in Clinical Samples.

Authors:  Roberta Noberini; Cristina Morales Torres; Evelyn Oliva Savoia; Stefania Brandini; Maria Giovanna Jodice; Giovanni Bertalot; Giuseppina Bonizzi; Maria Capra; Giuseppe Diaferia; Paola Scaffidi; Tiziana Bonaldi
Journal:  Int J Mol Sci       Date:  2020-10-04       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.